Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism

American Journal of Medicine

Volumn 105, Issue 6, 1998, Pages 472-477

  Meyer, Guy ^a   Gisselbrecht, Mathilde ^a   Diehl, Jean Luc ^a   Journois, Didier ^a   Sors, Hervé ^a  

^a Hopital Laennec   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLEEDING; FEMALE; FEMORAL VEIN; FIBRINOLYTIC THERAPY; HUMAN; INCIDENCE; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 0032411920     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00355-6     Document Type: Article

References (31)

1. 1. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: Randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993; 341:507-511.
2. 2. McIntyre KM, Sasahara AA. Hemodynamic and ventricular responses to pulmonary embolism. Prog Cardiovasc Dis. 1974;17: 175-190.
3. 3. Dalla-Volta S, Palla A, Santolicandro AM, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol. 1992;20:520-526.
4. 4. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol. 1992;19:239-245.
5. 5. Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus vs 2h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest. 1994;106:712-717.
6. 6. Levine MN, Goldhaber SZ, Gore JM, et al. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest. 1995;108:291S-301S.
7. 7. Landefeld CS, McGuire III E, Rosenblatt MW. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 1990;89:569-578.
8. 8. De Jaegere P, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictors factors. J Am Coll Cardiol. 1992;19:289-294.
9. 9. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-1 trial. Circulation. 1995;92:2811-2818.
10. 10. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342:1523-1528.
11. 11. Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest. 1997;111:1241-1245.
12. 12. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Ann Intern Med. 1994;121:313-317.
13. 13. Mikkola KM, Patel SR, Parker JA, et al. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J. 1997;134:69-72.
14. 14. Meyer G, Charbonnier B, Stern M, et al. Thrombolysis in acute pulmonary embolism. In: Julian DG, Kubler W, Norris RM, Swan HJ, Collen D, Verstraete M, eds. Thrombolysis in Cardiovascular Disease. New York: Marcel Dekker, 1989:337-360.
15. 15. Miller GAH, Sutton GC, Kerr IH, et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2:681-684.
16. 16. Meyer G, Collignon MA, Guinet F, et al. Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med. 1990;17: 315-319.
17. 17. Landefeld CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol. 1989;42:711-718.
18. 18. The Urokinase Pulmonary Embolism Trial. A National Cooperative Study. Circulation. 1973;47:1-108S.
19. 19. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98:1473-1479.
20. 20. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs. conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicentre randomized study. Chest. 1994;106:718-724.
21. 21. Norusis MJ. Logistic regression analysis. In: SPSS-X Advanced Statistics Student Guide. Chicago: SPSS, 1990:119-146.
22. 22. Cohen J. A coefficient of agreement for nominal scales. Educ Psych Meas. 1960;20:37-46.
23. 23. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. NEJM. 1993;329:673-682.
24. 24. Gruppo Italiano per lo studio della Sofravvivenza nell'Infarto Miocardico GISSI-2. A factorial randomized trial of anistreplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-81.
25. 25. ISIS 3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
26. 26. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. NEJM. 1997;336:847-860.
27. 27. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988;ii: 293-298.
28. 28. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992;20:24-30.
29. 29. Perrier A, Bounameaux H, Morabia A, et al. Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability, D-Dimer levels, and ultrasonography: a management study. Arch Intern Med. 1996;156:531-536.
30. 30. The UKEP study research group. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. Eur Heart J. 1987;8:2-10.
31. 31. Verstraete M, Miller GAH, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation. 1988;77:353-360.